Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mo Youl Beck

Phase II Trial of Continuous Regorafenib Dosing in Patients With Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

Oncologist

English

Related publications

Regorafenib for Advanced Gastrointestinal Stromal Tumors Following Imatinib and Sunitinib Treatment: A Subgroup Analysis Evaluating Japanese Patients in the Phase III GRID Trial

International Journal of Clinical Oncology

English

Phase II Trial of Imatinib in Metastatic or Unresectable Gastrointestinal Stromal Tumors,NEMROCK Experience.

Research in Oncology

2006

English

Comparison of Performance of Various Tumour Response Criteria in Assessment of Regorafenib Activity in Advanced Gastrointestinal Stromal Tumours After Failure of Imatinib and Sunitinib

European Journal of Cancer

Cancer Research

Oncology

2014

English

Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial

European Journal of Cancer

Cancer Research

Oncology

2019

English

Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–resistant Patients: Recommendations and Evidence

Current Oncology

Oncology

2010

English

Genetic Polymorphisms as Predictive Biomarker of Survival in Patients With Gastrointestinal Stromal Tumors Treated With Sunitinib

Pharmacogenomics Journal

English

Clinical Benefit of Sunitinib in Gastrointestinal Stromal Tumors With Different Exon 11 Mutation Genotypes

English

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors

Journal of Gastrointestinal Surgery

Surgery

Gastroenterology

2013

English

Gastrointestinal Stromal Tumors Treated With Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Mo Youl Beck

Phase II Trial of Continuous Regorafenib Dosing in Patients With Gastrointestinal Stromal Tumors After Failure of Imatinib and Sunitinib

Related publications

Regorafenib for Advanced Gastrointestinal Stromal Tumors Following Imatinib and Sunitinib Treatment: A Subgroup Analysis Evaluating Japanese Patients in the Phase III GRID Trial

Phase II Trial of Imatinib in Metastatic or Unresectable Gastrointestinal Stromal Tumors,NEMROCK Experience.

Comparison of Performance of Various Tumour Response Criteria in Assessment of Regorafenib Activity in Advanced Gastrointestinal Stromal Tumours After Failure of Imatinib and Sunitinib

Efficacy and Safety of TAS-116, an Oral Inhibitor of Heat Shock Protein 90, in Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumour Refractory to Imatinib, Sunitinib and Regorafenib: A Phase II, Single-Arm Trial

Sunitinib Malate for Gastrointestinal Stromal Tumour in Imatinib Mesylate–resistant Patients: Recommendations and Evidence

Genetic Polymorphisms as Predictive Biomarker of Survival in Patients With Gastrointestinal Stromal Tumors Treated With Sunitinib

Clinical Benefit of Sunitinib in Gastrointestinal Stromal Tumors With Different Exon 11 Mutation Genotypes

Optimizing Surgical and Imatinib Therapy for the Treatment of Gastrointestinal Stromal Tumors

Gastrointestinal Stromal Tumors Treated With Imatinib Mesylate: Apparent Diffusion Coefficient in the Evaluation of Therapy Response in Patients